Key facts
- This page summarizes Christopher Ryan Sullivan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2026, 16:10.
Christopher Ryan Sullivan - 17 Aug 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- AVTX
- Reported as of
- 17 Aug 2026
- Net transaction value
- -$1,450,419
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2026, 16:10:18 UTC
- Prior SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Sullivan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Ryan Sullivan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 19 Aug 2026.
Change
- Previous filing in this sequence was filed on 12 Jun 2026.
- Current net transaction value: -$1,450,419.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001810417
Primary reporting owner
Sullivan Christopher Ryan
- Relationship
- Chief Financial Officer
- Address
- C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
- Signature
- /s/ Christopher Sullivan
- Signature date
- 19 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +37,945
- Change %
- +93%
- Price
- $9.88*
- Shares after
- 78,718
- Date
- 17 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
AVTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,876
- Change %
- +3.7%
- Price
- $9.88*
- Shares after
- 81,594
- Date
- 17 Aug 2026
- Ownership
- Direct
AVTX
transaction
Common Stock
Sale
- Transaction value
- $753,333
- Shares
- -37,945
- Change %
- -47%
- Price
- $19.85
- Shares after
- 43,649
- Date
- 17 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
AVTX
transaction
Common Stock
Sale
- Transaction value
- $74,762
- Shares
- -3,749
- Change %
- -8.6%
- Price
- $19.94
- Shares after
- 39,900
- Date
- 17 Aug 2026
- Ownership
- Direct
- Footnotes
- F3
AVTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +31,031
- Change %
- +78%
- Price
- $9.88*
- Shares after
- 70,931
- Date
- 18 Aug 2026
- Ownership
- Direct
AVTX
transaction
Common Stock
Sale
- Transaction value
- $622,324
- Shares
- -31,031
- Change %
- -44%
- Price
- $20.05
- Shares after
- 39,900
- Date
- 18 Aug 2026
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -37,945
- Change %
- -23%
- Price
- $0.000000*
- Shares after
- 130,149
- Date
- 17 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,945
- Exercise price
- $9.88
- Footnotes
- F1, F5
AVTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -2,876
- Change %
- -2.2%
- Price
- $0.000000*
- Shares after
- 127,273
- Date
- 17 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,876
- Exercise price
- $9.88
- Footnotes
- F5
AVTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -31,031
- Change %
- -24%
- Price
- $0.000000*
- Shares after
- 96,242
- Date
- 18 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,031
- Exercise price
- $9.88
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
Footnote F2
The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Footnote F3
The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Footnote F4
The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Footnote F5
The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.